NEW YORK, July 9 - Millennium Pharmaceuticals has agreed to license the BioRS data integration and retrieval system from Biomax, the companies said Monday.
BioRS integrates public and proprietary biological databases through a web interface. The system uses XML to standardize the data format, and can integrate both relational and flat-file databases. In January, Informax signed a four-year deal with Biomax, based in Martinsried, to exclusively license and distribute the BioRS system worldwide.
"We performed an extensive analysis of the BioRS system over several months and it proved to be a stable, comprehensive, and efficient system. The speed and agility with which we assess drug targets in our gene-to-patient platform requires a system that can handle a broad spectrum of user scenarios for large data volumes," Tim Clark, vice president for informatics at Millennium, said in a statement.
In a separate announcement, Biomax said Monday that it had agreed to collaborate with Molecular Networks to develop software for integrating drug target lead identification and validation data.
Molecular Networks, of Erlangen, Germany, has developed chemoinformatics software for applications such as generating three-dimensional molecular models, comparing libraries of compounds, and simulating chemical reaction and metabolic pathways. Because Biomax has focused on developing software for sequence analysis and other genomic data manipulation, the two companies hope to combine their respective expertise to create an integrated platform.
Financial details of the arrangement were not disclosed.
"Although the two companies have been sharing resources for quite some time, this formal agreement, complete with milestones, will give better focus and direction to new product development," Johann Gasteiger, CEO of Molecular Networks, said in a statement.
"Until now, bioinformatics and chemoinformatics have been treated as separate entities," added Klaus Heumann, CEO of Biomax. "Our customers have already started asking for such software integration and this arrangement with Molecular Networks was an obvious and natural next step in our product development process."